| Q46879698 | 14-3-3- and II/3-10-gene expression as molecular markers to address viability and growth activity of Echinococcus multilocularis metacestodes. |
| Q37417747 | Alveolar and cystic echinococcosis: towards novel chemotherapeutical treatment options |
| Q36158222 | Arsenic trioxide negatively affects Echinococcus granulosus |
| Q37777593 | Clinical features and treatment of alveolar echinococcosis |
| Q28080010 | Current status of diagnosis and treatment of hepatic echinococcosis |
| Q48586593 | Development of antiparasitic drugs in the 21st century |
| Q37599990 | Echinococcus metacestodes as laboratory models for the screening of drugs against cestodes and trematodes. |
| Q81585274 | Echinococcus multilocularis: immunity response to purified alkaline phosphatase in BALB/c mice |
| Q60910098 | Effect of anacardic acid against echinococcosis through inhibition of VEGF-induced angiogenesis |
| Q40579373 | Efficacy of osthole for Echinococcus granulosus in vitro and Echinococcus multilocularis in vivo |
| Q37169024 | Evaluation of nitazoxanide and oxfendazole efficacy against cystic echinococcosis in naturally infected sheep |
| Q34531388 | Evaluation of nitazoxanide for the treatment of disseminated cystic echinococcosis: report of five cases and literature review |
| Q24601200 | In vitro Effects of Albendazole on Raillietina echinobothrida, the Cestode of Chicken, Gallus domesticus |
| Q37036612 | In vitro and in vivo activities of dicationic diguanidino compounds against Echinococcus multilocularis metacestodes |
| Q34529138 | In vitro and in vivo efficacies of mefloquine-based treatment against alveolar echinococcosis. |
| Q36870795 | In vitro and in vivo treatments of echinococcus protoscoleces and metacestodes with artemisinin and artemisinin derivatives |
| Q37126071 | In vitro culture of Echinococcus multilocularis producing protoscoleces and mouse infection with the cultured vesicles |
| Q44999194 | In vitro effects of nitazoxanide on Echinococcus granulosus protoscoleces and metacestodes |
| Q38627137 | In vitro efficacy of dicationic compounds and mefloquine enantiomers against Echinococcus multilocularis metacestodes |
| Q42272747 | In vitro efficacy of triclabendazole and clorsulon against the larval stage of Echinococcus multilocularis |
| Q57253118 | In vitro induction of lymph node cell proliferation by mouse bone marrow dendritic cells following stimulation with different Echinococcus multilocularis antigens |
| Q24674880 | In vitro metacestodicidal activities of genistein and other isoflavones against Echinococcus multilocularis and Echinococcus granulosus |
| Q44102388 | In vivo albendazole treatment of Taenia crassiceps cysticerci strain WFU: proliferation, damage, and recovery. |
| Q42932773 | In vivo study of the efficacy of the aromatic water of Zataria multiflora on hydatid cysts |
| Q36882080 | Innovative chemotherapeutical treatment options for alveolar and cystic echinococcosis |
| Q36228901 | Isolation and characterization of a secretory component of Echinococcus multilocularis metacestodes potentially involved in modulating the host-parasite interface |
| Q46126127 | Limitations of amphotericin B and nitazoxanide in the treatment of alveolar echinococcosis |
| Q36275299 | Metformin exhibits preventive and therapeutic efficacy against experimental cystic echinococcosis |
| Q42645521 | Mitochondrial ribosome as the target for the macrolide antibiotic clarithromycin in the helminth Echinococcus multilocularis |
| Q28236279 | Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections |
| Q28287647 | Nitazoxanide: a new broad spectrum antiparasitic agent |
| Q46404981 | Nitazoxanide: a new thiazolide antiparasitic agent |
| Q38294864 | On the importance of targeting parasite stem cells in anti-echinococcosis drug development. |
| Q35656796 | Prevention and Immunotherapy of Secondary Murine Alveolar Echinococcosis Employing Recombinant EmP29 Antigen |
| Q87459127 | Preventive and therapeutic effects of Zataria multiflora methanolic extract on hydatid cyst: an in vivo study |
| Q28542496 | Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes |
| Q36558399 | Quantitative screening for anticestode drugs based on changes in baseline enzyme secretion by Taenia crassiceps |
| Q26795698 | Recent advances in Echinococcus genomics and stem cell research |
| Q26823355 | Repurposing drugs for the treatment and control of helminth infections |
| Q58584921 | Repurposing of an old drug: In vitro and in vivo efficacies of buparvaquone against Echinococcus multilocularis |
| Q34483571 | Sensitive in vitro system to assess morphological and biochemical effects of praziquantel and albendazole on Taenia solium cysts. |
| Q28539389 | Targeting Echinococcus multilocularis stem cells by inhibition of the Polo-like kinase EmPlk1 |
| Q36847635 | The Ultrastructural Effects of Sulfachloropyrazine on Toxoplasma gondii Tachyzoites |
| Q89869922 | The importance of being parasiticidal… an update on drug development for the treatment of alveolar echinococcosis |
| Q41910613 | Tizoxanide pyridine monosolvate |
| Q34741945 | Treatment of echinococcosis: albendazole and mebendazole--what else? |
| Q90442664 | Ultrastructural changes in hydatid cyst walls obtained from human cases, exposed to different therapeutic approaches |
| Q40344726 | Use of nitazoxanide for gastrointestinal tract infections: treatment of protozoan parasitic infection and beyond |